| Full Name | Michael Chen |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 8 Years |
| Location | 475 W 940 N, Provo, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174985808 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 10395937-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Utah Hospitals And Clinics | Salt lake city, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Utah Community Physicians Group | 9739403569 | 257 |
News Archive
A new study examines the effectiveness of 3D printing technology and computer modeling to predict paravalvular leak in patients undergoing transcatheter aortic valve replacement (TAVR). A common risk of TAVR is an ill-fitting valve which can lead to PVL.
Supervised exercise was shown to be more effective than stenting or medication for improved walking ability in patients with peripheral artery disease. The findings from a national study were reported today at the 2011 American Heart Association Scientific Sessions meeting.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces completion of patient enrollment in the phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Pathway Therapeutics, a drug discovery and development company founded in New Zealand, announced that it has met an important drug development milestone triggering a US$4.5 million fourth tranche of its Series A private equity placement. The financing was led by GBS Venture Partners, Australia and CM Capital Investments, Australia with co-investors the Breast Cancer Research Trust, the Trans-Tasman Commercialisation Fund, and the New Zealand Venture Investment Firm.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2010.
› Verified 1 days ago
| Entity Name | University Of Utah Community Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598169203 PECOS PAC ID: 9739403569 Enrollment ID: O20150126002118 |
News Archive
A new study examines the effectiveness of 3D printing technology and computer modeling to predict paravalvular leak in patients undergoing transcatheter aortic valve replacement (TAVR). A common risk of TAVR is an ill-fitting valve which can lead to PVL.
Supervised exercise was shown to be more effective than stenting or medication for improved walking ability in patients with peripheral artery disease. The findings from a national study were reported today at the 2011 American Heart Association Scientific Sessions meeting.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces completion of patient enrollment in the phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Pathway Therapeutics, a drug discovery and development company founded in New Zealand, announced that it has met an important drug development milestone triggering a US$4.5 million fourth tranche of its Series A private equity placement. The financing was led by GBS Venture Partners, Australia and CM Capital Investments, Australia with co-investors the Breast Cancer Research Trust, the Trans-Tasman Commercialisation Fund, and the New Zealand Venture Investment Firm.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2010.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Chen, Po Box 27128, Salt Lake City, UT 84127-0128 Ph: () - | Michael Chen, 475 W 940 N, Provo, UT 84604-3301 Ph: (801) 357-7940 |
News Archive
A new study examines the effectiveness of 3D printing technology and computer modeling to predict paravalvular leak in patients undergoing transcatheter aortic valve replacement (TAVR). A common risk of TAVR is an ill-fitting valve which can lead to PVL.
Supervised exercise was shown to be more effective than stenting or medication for improved walking ability in patients with peripheral artery disease. The findings from a national study were reported today at the 2011 American Heart Association Scientific Sessions meeting.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces completion of patient enrollment in the phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Pathway Therapeutics, a drug discovery and development company founded in New Zealand, announced that it has met an important drug development milestone triggering a US$4.5 million fourth tranche of its Series A private equity placement. The financing was led by GBS Venture Partners, Australia and CM Capital Investments, Australia with co-investors the Breast Cancer Research Trust, the Trans-Tasman Commercialisation Fund, and the New Zealand Venture Investment Firm.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2010.
› Verified 1 days ago
Dr. Robert Joel Bush, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 750 N Freedom Blvd Ste 300, Provo, UT 84601 Phone: 801-852-1443 | |
Janee Namealoha Sells, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 3200 N Canyon Rd Ste C, Provo, UT 84604 Phone: 385-375-8724 | |
Dr. Marlin L Christianson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 475 West 940 North, Provo, UT 84604 Phone: 801-357-7930 Fax: 801-357-7014 | |
Tyson Schwab, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 395 W Bulldog Blvd Ste 205, Provo, UT 84604 Phone: 801-357-1770 | |
Mr. Gregory Lawrence Nielsen, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1750 N Wymount Terrace Dr, Provo, UT 84604 Phone: 801-422-2771 Fax: 801-422-0761 | |
Mr. Tyler Jason Fieldsted, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 475 W 940 N, Provo, UT 84604 Phone: 801-357-7926 Fax: 801-357-7927 | |
Dr. Matthew Craig Evans, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1157 N 300 W, #201, Provo, UT 84604 Phone: 801-581-2000 |